MA33764B1 - Procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle et de purification de celui-ci en vue de son utilisation comme principe actif pharmaceutique - Google Patents
Procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle et de purification de celui-ci en vue de son utilisation comme principe actif pharmaceutiqueInfo
- Publication number
- MA33764B1 MA33764B1 MA34893A MA34893A MA33764B1 MA 33764 B1 MA33764 B1 MA 33764B1 MA 34893 A MA34893 A MA 34893A MA 34893 A MA34893 A MA 34893A MA 33764 B1 MA33764 B1 MA 33764B1
- Authority
- MA
- Morocco
- Prior art keywords
- fluorobenzyl
- purification
- berzolo
- berdine
- pyridimine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
)la présente invention concerne un procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle, à savoir du composé de formule (i), ainsi qu'un procédé de purification du produit brut de formule (i) pour l'utilisation comme principe pharmaceutiquement actif, à l'occasion de quoi pour la purification du {4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle-sulfinyldiméthane (1 :2) de formule (ii) est isolé comme stade intermédiaire ou est produit, le cas échéant présent dans un mélange, comme stade intermédiaire dans ce procédé de purification.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09177369 | 2009-11-27 | ||
PCT/EP2010/067884 WO2011064156A2 (fr) | 2009-11-27 | 2010-11-22 | Procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle et de purification de celui-ci en vue de son utilisation comme principe actif pharmaceutique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33764B1 true MA33764B1 (fr) | 2012-11-01 |
Family
ID=43568194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34893A MA33764B1 (fr) | 2009-11-27 | 2012-05-25 | Procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle et de purification de celui-ci en vue de son utilisation comme principe actif pharmaceutique |
Country Status (22)
Country | Link |
---|---|
US (1) | US8501945B2 (fr) |
EP (1) | EP2504335B1 (fr) |
JP (1) | JP2013512211A (fr) |
KR (1) | KR20120098815A (fr) |
CN (1) | CN102712637A (fr) |
AR (1) | AR079135A1 (fr) |
AU (1) | AU2010323297A1 (fr) |
BR (1) | BR112012012618A2 (fr) |
CA (1) | CA2781922A1 (fr) |
CO (1) | CO6551707A2 (fr) |
CU (1) | CU20120083A7 (fr) |
DO (1) | DOP2012000143A (fr) |
EA (1) | EA201270639A1 (fr) |
EC (1) | ECSP12011920A (fr) |
ES (1) | ES2433236T3 (fr) |
IL (1) | IL219861A0 (fr) |
MA (1) | MA33764B1 (fr) |
MX (1) | MX2012005942A (fr) |
TN (1) | TN2012000259A1 (fr) |
TW (1) | TW201200513A (fr) |
UY (1) | UY33041A (fr) |
WO (1) | WO2011064156A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS59908B1 (sr) | 2009-11-27 | 2020-03-31 | Adverio Pharma Gmbh | Postupak za proizvodnju metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
JP6189315B2 (ja) | 2011-11-25 | 2017-08-30 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換された5−フルオロ−1h−ピラゾロピリジン類を製造するための方法 |
BR112015019571A2 (pt) * | 2013-02-21 | 2017-07-18 | Adverio Pharma Gmbh | formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
CN108069960A (zh) * | 2016-11-15 | 2018-05-25 | 江苏豪森药业集团有限公司 | 利奥西呱中间体的制备方法 |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
JP2021530491A (ja) | 2018-07-11 | 2021-11-11 | サイクレリオン・セラピューティクス,インコーポレーテッド | ミトコンドリア(mitochonrial)障害の処置のためのsGC刺激剤の使用 |
EP3925953A1 (fr) * | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Procédé de préparation de méthyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
JP4351298B2 (ja) | 1996-10-14 | 2009-10-28 | バイエル・アクチエンゲゼルシヤフト | 新規へテロシクリルメチル置換ピラゾール誘導体 |
DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
EP1049695B1 (fr) | 1997-11-12 | 2002-02-13 | Bayer Ag | Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE10351903A1 (de) | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) * | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102009004245A1 (de) * | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
-
2010
- 2010-11-19 UY UY0001033041A patent/UY33041A/es not_active Application Discontinuation
- 2010-11-22 WO PCT/EP2010/067884 patent/WO2011064156A2/fr active Application Filing
- 2010-11-22 KR KR1020127016592A patent/KR20120098815A/ko not_active Application Discontinuation
- 2010-11-22 JP JP2012540378A patent/JP2013512211A/ja active Pending
- 2010-11-22 BR BR112012012618A patent/BR112012012618A2/pt not_active IP Right Cessation
- 2010-11-22 ES ES10781894T patent/ES2433236T3/es active Active
- 2010-11-22 CN CN2010800537100A patent/CN102712637A/zh active Pending
- 2010-11-22 CA CA2781922A patent/CA2781922A1/fr not_active Abandoned
- 2010-11-22 EP EP10781894.0A patent/EP2504335B1/fr active Active
- 2010-11-22 EA EA201270639A patent/EA201270639A1/ru unknown
- 2010-11-22 MX MX2012005942A patent/MX2012005942A/es unknown
- 2010-11-22 AU AU2010323297A patent/AU2010323297A1/en not_active Abandoned
- 2010-11-24 AR ARP100104327A patent/AR079135A1/es unknown
- 2010-11-26 TW TW099140891A patent/TW201200513A/zh unknown
- 2010-11-29 US US12/955,864 patent/US8501945B2/en active Active
-
2012
- 2012-05-17 IL IL219861A patent/IL219861A0/en unknown
- 2012-05-23 EC ECSP12011920 patent/ECSP12011920A/es unknown
- 2012-05-24 TN TNP2012000259A patent/TN2012000259A1/en unknown
- 2012-05-24 DO DO2012000143A patent/DOP2012000143A/es unknown
- 2012-05-24 CO CO12085979A patent/CO6551707A2/es not_active Application Discontinuation
- 2012-05-24 CU CU2012000083A patent/CU20120083A7/es unknown
- 2012-05-25 MA MA34893A patent/MA33764B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2781922A1 (fr) | 2011-06-03 |
US8501945B2 (en) | 2013-08-06 |
MX2012005942A (es) | 2012-10-03 |
WO2011064156A3 (fr) | 2011-10-20 |
ES2433236T3 (es) | 2013-12-10 |
US20110130411A1 (en) | 2011-06-02 |
UY33041A (es) | 2011-06-30 |
EP2504335B1 (fr) | 2013-09-04 |
AU2010323297A1 (en) | 2012-06-14 |
TN2012000259A1 (en) | 2013-12-12 |
EP2504335A2 (fr) | 2012-10-03 |
WO2011064156A2 (fr) | 2011-06-03 |
CN102712637A (zh) | 2012-10-03 |
IL219861A0 (en) | 2012-07-31 |
EA201270639A1 (ru) | 2013-01-30 |
ECSP12011920A (es) | 2012-07-31 |
TW201200513A (en) | 2012-01-01 |
BR112012012618A2 (pt) | 2015-09-08 |
CU20120083A7 (es) | 2012-10-15 |
CO6551707A2 (es) | 2012-10-31 |
JP2013512211A (ja) | 2013-04-11 |
KR20120098815A (ko) | 2012-09-05 |
DOP2012000143A (es) | 2013-01-31 |
AR079135A1 (es) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33764B1 (fr) | Procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle et de purification de celui-ci en vue de son utilisation comme principe actif pharmaceutique | |
MA33783B1 (fr) | Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique | |
MX2023005362A (es) | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. | |
SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
NO20076597L (no) | Fremgangsmater for fremstilling av 4-(bifenylyl)azetidin-2-one fosforsyrer | |
SI2091948T1 (sl) | Novi inhibitorji glutaminil ciklaze | |
TNSN08170A1 (en) | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | |
NO20091858L (no) | Hydrobenzamid derivater som inhibitorer av HSP90 | |
TN2009000401A1 (en) | New methods | |
WO2013190298A1 (fr) | Composés 2h-imidazol-4-amine et leur utilisation en tant qu'inhibiteurs de bace | |
MA29943B1 (fr) | Derives de pyrazolo[4,3-d] pyrimidine-5-yle utilises comme inhibiteurs de pde5 | |
ATE394379T1 (de) | 4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung | |
EP2861071A1 (fr) | Inhibiteurs d'aldostérone synthase | |
WO2009038157A1 (fr) | Dérivé de 2,3-dihydroiminoisoindole | |
WO2003075907A3 (fr) | Inhibiteurs de la penetration de petites molecules | |
ATE532516T1 (de) | Verfahren zur synthese von glyt-1-hemmern | |
DE60209122D1 (de) | Bernsteinsäurederivate | |
EA200970496A1 (ru) | Соединения 2-алкилиндазола для лечения некоторых расстройств цнс | |
NO20055755L (no) | Nytt intermediat for fremstillingen av terapeutisk aktive imidazopyridiner | |
UA93030C2 (ru) | Способ получения клопидогрела (варианты) и промежуточные соединения | |
NO20064580L (no) | Fremgangsmate for fremstilling av cefalosporinintermediater ved anvendelse av alfa-jodo-1-azetidin eddiksyreestere og trialkylfosfitter | |
TH73095A (th) | กระบวนการทางเคมีและอินเทอร์มีเดียต | |
ATE467628T1 (de) | Benzimidazolverbindungen | |
TH77085A (th) | กรรมวิธีสำหรับการเตรียม 2-ไซยาโน-3-แนฟธาลีน-1-อิล-3-เฟนิล-โพรพิโอนิค แอซิด แอลคิลหรือเบนซิล เอสเทอร์ | |
TH127244A (th) | อนุพันธ์ของอิมิดาโซ[1,2-a]ไพราซีนและการใช้ของสิ่งนั้นที่เป็นสารยับยั้ง PDE10 |